# Novartis CEO Pitches AI as Key to Faster Drug Development and Curing ‘Biological Latency’

On the day that AI giant Anthropic staged a record-breaking IPO on Nasdaq, Novartis CEO Vas Narasimhan, who also sits on Anthropic’s board, was in London pitching investors on how the Swiss drugmaker is using artificial intelligence to shrink drug development timelines and eventually solve “biological latency.”

Narasimhan is Anthropic’s lone pharmaceutical board member. His dual role highlights the growing intersection between big pharma and frontier AI companies. The Novartis chief outlined a vision in which AI models could dramatically accelerate the pace of discovering and validating new medicines, addressing what he described as a fundamental bottleneck in drug R&D.

The term “biological latency” refers to the long, unpredictable delays between understanding a disease mechanism and delivering a working therapy to patients. By applying generative and predictive AI to the earliest stages of drug design, Novartis aims to compress those timelines.

**Why this matters for life sciences:** Drug development typically takes a decade or more and carries high failure rates. AI tools that can analyze vast biological datasets, predict molecular interactions, and simulate clinical outcomes hold promise for reducing both time and cost. If large-scale models like those developed by Anthropic can be reliably applied to biology, the industry could see a shift toward faster candidate selection and more targeted therapies. Narasimhan’s position at both Novartis and Anthropic signals that drugmakers are betting on general-purpose AI platforms to transform how new treatments are conceived and tested.

Source: [original report](https://www.fiercebiotech.com/biotech/anthropic-board-director-vas-narasimhan-bets-ai-can-help-novartis-solve-biological-latency)